JB Capital LLC Raises Stock Holdings in Medtronic PLC $MDT

JB Capital LLC boosted its position in Medtronic PLC (NYSE:MDT) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,310 shares of the medical technology company’s stock after purchasing an additional 8,695 shares during the quarter. JB Capital LLC’s holdings in Medtronic were worth $14,055,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Savvy Advisors Inc. boosted its stake in Medtronic by 85.4% during the fourth quarter. Savvy Advisors Inc. now owns 29,777 shares of the medical technology company’s stock worth $2,860,000 after acquiring an additional 13,716 shares in the last quarter. SS&H Financial Advisors Inc. increased its stake in shares of Medtronic by 9.2% during the fourth quarter. SS&H Financial Advisors Inc. now owns 17,871 shares of the medical technology company’s stock valued at $1,717,000 after purchasing an additional 1,500 shares in the last quarter. Stratos Investment Management LLC lifted its holdings in shares of Medtronic by 1.1% during the fourth quarter. Stratos Investment Management LLC now owns 34,634 shares of the medical technology company’s stock valued at $3,327,000 after purchasing an additional 376 shares during the last quarter. Red Door Wealth Management LLC lifted its holdings in shares of Medtronic by 5.8% during the fourth quarter. Red Door Wealth Management LLC now owns 4,357 shares of the medical technology company’s stock valued at $419,000 after purchasing an additional 240 shares during the last quarter. Finally, Trust Co. of Toledo NA OH boosted its position in shares of Medtronic by 53.5% in the 4th quarter. Trust Co. of Toledo NA OH now owns 24,750 shares of the medical technology company’s stock worth $2,377,000 after purchasing an additional 8,621 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $86.61 on Friday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a market capitalization of $111.19 billion, a P/E ratio of 24.12, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. The firm has a 50 day moving average of $94.47 and a 200 day moving average of $96.24. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the prior year, the firm posted $1.38 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. UBS Group restated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. Needham & Company LLC reissued a “buy” rating and issued a $120.00 target price on shares of Medtronic in a report on Thursday, March 26th. Robert W. Baird cut their target price on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Citigroup initiated coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target for the company. Finally, Sanford C. Bernstein lifted their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $109.85.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is owned by company insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).